by Jon Fleetwood, Jon Fleetwood:
Court affirms injured patients’ right to access manufacturer data, forcing disclosure.
In a major procedural victory for vaccine-injured plaintiffs, a German court has ordered BioNTech to turn over internal data on its Comirnaty mRNA COVID-19 vaccine—affirming that individuals claiming harm have the right to access the manufacturer’s own records to challenge its safety claims and pursue damages.
The Regional Court of Aurich (Landgericht Aurich), in case 5 O 1106/24, issued a certified partial judgment (“Teilurteil”) ordering BioNTech Manufacturing GmbH to provide detailed information on the vaccine’s effects, side effects, and underlying biological and manufacturing characteristics.
TRUTH LIVES on at https://sgtreport.tv/
The court’s order states, translated and paraphrased for readability:
The defendant is ordered … to provide information … on the effects and side effects known to it … as well as on other findings that may be relevant for the assessment of the justifiability of harmful effects …
The ruling directly addresses a core imbalance that has defined vaccine injury litigation: injured individuals have been expected to prove causation while being denied access to the very data needed to do so.
This decision breaks that barrier.
Independent journalist Bastian Barucker first reported on the ruling.
Court Order Forces Disclosure Across Manufacturing, Biology, and Safety
The certified judgment (“Beglaubigte Abschrift”)—posted by Tobias Ulbrich (@AnwaltUlbrich), the plaintiff’s lead lawyer from Rogert & Ulbrich—shows the court is not ordering narrow or limited disclosure.
It is compelling BioNTech to provide specific, technical categories of internal data, including:
- Toxicity and immunological effects of lipid nanoparticles (ALC-0159, ALC-0315)
- Pharmaceutical purity and variability of key components
- Manufacturing processes, suppliers, and batch-level differences
- Residual DNA contamination and sequencing data (“Process 2”)
- Spike protein design, function, and biological behavior (including ACE2 interaction and cleavage mechanisms)
- Whether spike protein remains membrane-bound or becomes freely circulating in the body
- Biodistribution and potential exposure of organs and tissues
- Pharmacovigilance data on recorded injuries matching the plaintiff’s conditions
- Genotoxicity findings in humans
- Reproductive and fertility-related effects
- Sex-based risk differences, including higher risk signals in women
- Cancer-related mechanisms, including P53 interaction and oncomiR findings
- Internal evaluations tied to risk-benefit assessments
- Batch-specific quality control and contamination measurements
- Quantification of spike protein production in the body
These categories align with a broader disclosure request submitted by the plaintiff—commonly circulated as a “32-point” data list—now substantiated by the court’s order itself.
Plaintiff Presented Evidence of Severe Post-Vaccination Injury
The case involves a woman who received two doses of Comirnaty in 2021 and subsequently developed multiple conditions, including:
- Autoimmune disease
- Circulatory disorders
- Vascular occlusion
- Cardiac arrhythmias
- Hyperinflammation syndrome
- Neurological dysfunction
- Menstrual disruption
Court records indicate no clear pre-existing conditions prior to vaccination.
Read More @ jonfleetwood.substack.com
